Acadia reported that its mid-stage trial failed to meet the primary endpoint for reducing hallucinations and delusions in Alzheimer's-related psychosis. The setback undermines confidence in the lead program and could compress ACAD's valuation and funding runway. Management commentary on next steps, data readouts, and potential strategic options will shape the stock's near-term trajectory.
ACADIA shares rise after the CHMP recommends EU marketing authorization for DAYBU trofinetide, buoyed by positive LAVENDER Phase 3 results. With the stock trading around $26.57 and approaching $28 resistance, momentum looks strong but overbought, while a death cross warns of longer-term caution.
ACAD's Phase 3 trial for carbetocin failed primary efficacy endpoint. CEO assures long-term growth despite recent trial results. Company expects significant sales growth and multiple new study starts by 2026. ACAD stock dropped 11.02% premarket following trial results. Competitor Soleno Therapeutics faces scrutiny for its PWS treatment.
ACAD secured a favorable court ruling for NUPLAZID's patent protection. The ruling extends protection against generics until 2038. ACAD shares rose by 26.5% following the announcement. Analysts raised price targets for ACADIA after the ruling. Needham and HC Wainwright maintain 'Buy' ratings on ACAD.
